PTC Therapeutics Inc (PTCT)vsVertex Pharmaceuticals Inc (VRTX)
PTCT
PTC Therapeutics Inc
$66.75
+3.42%
HEALTHCARE · Cap: $5.34B
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 593% more annual revenue ($12.00B vs $1.73B). PTCT leads profitability with a 39.4% profit margin vs 32.9%. PTCT appears more attractively valued with a PEG of 0.81. VRTX earns a higher WallStSmart Score of 66/100 (B-).
PTCT
Hold45
out of 100
Grade: D
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-21.6%
Fair Value
$58.34
Current Price
$66.75
$8.41 premium
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Keeps 39 of every $100 in revenue as profit
Growing faster than its price suggests
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
ROE of -77.4% — below average capital efficiency
Revenue declined 22.7%
Negative free cash flow — burning cash
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : PTCT
The strongest argument for PTCT centers on P/E Ratio, Profit Margin, PEG Ratio. Profitability is solid with margins at 39.4% and operating margin at -49.6%. PEG of 0.81 suggests the stock is reasonably priced for its growth.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : PTCT
The primary concerns for PTCT are EPS Growth, Return on Equity, Revenue Growth.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
PTCT profiles as a declining stock while VRTX is a mature play — different risk/reward profiles.
PTCT carries more volatility with a beta of 0.56 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 45/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
PTC Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. The company is headquartered in South Plainfield, New Jersey.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?